ATE420878T1 - Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente - Google Patents

Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente

Info

Publication number
ATE420878T1
ATE420878T1 AT01904545T AT01904545T ATE420878T1 AT E420878 T1 ATE420878 T1 AT E420878T1 AT 01904545 T AT01904545 T AT 01904545T AT 01904545 T AT01904545 T AT 01904545T AT E420878 T1 ATE420878 T1 AT E420878T1
Authority
AT
Austria
Prior art keywords
group
atom
isoxazole
thiazole compounds
optionally substituted
Prior art date
Application number
AT01904545T
Other languages
English (en)
Inventor
Akihiro Ueno
Rika Nagao
Tomoko Watanabe
Hideo Ohta
Mikio Yagi
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE420878T1 publication Critical patent/ATE420878T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT01904545T 2000-02-18 2001-02-19 Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente ATE420878T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000041922 2000-02-18

Publications (1)

Publication Number Publication Date
ATE420878T1 true ATE420878T1 (de) 2009-01-15

Family

ID=18565067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01904545T ATE420878T1 (de) 2000-02-18 2001-02-19 Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente

Country Status (11)

Country Link
US (1) US6964975B2 (de)
EP (1) EP1258484B1 (de)
AT (1) ATE420878T1 (de)
AU (1) AU2001232340A1 (de)
CY (1) CY1110263T1 (de)
DE (1) DE60137405D1 (de)
DK (1) DK1258484T3 (de)
ES (1) ES2320320T3 (de)
PT (1) PT1258484E (de)
TW (1) TWI288136B (de)
WO (1) WO2001060819A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7064217B2 (en) 2001-01-30 2006-06-20 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
DE60234318D1 (de) * 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
ATE406915T1 (de) * 2001-07-17 2008-09-15 Ono Pharmaceutical Co Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler
JP4596314B2 (ja) * 2002-05-28 2010-12-08 小野薬品工業株式会社 β−アラニン誘導体およびその用途
WO2004002530A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 慢性疾患治療剤
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
EP1546110A4 (de) 2002-07-30 2008-03-26 Univ Virginia Verbindungen mit wirkung bei der signalübertragung mittels sphingosin-1-phosphat
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ1ライアノジン受容体に基づく方法
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7524638B1 (en) 2003-06-27 2009-04-28 Osi Pharmaceuticals, Inc. Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease
WO2005012269A1 (ja) * 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに5員の複素環を含むスフィンゴシン=1−リン酸アゴニスト
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
FR2889190A1 (fr) 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
MX2008009579A (es) 2006-01-27 2008-09-25 Univ Virginia Metodo para el tratamiento de dolor neuropatico.
WO2007092638A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
WO2008064337A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
JP2010510249A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン=1−燐酸アゴニスト活性を有するテトラリンアナログ
JP2010510250A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン=1−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
CN105418450A (zh) * 2008-05-05 2016-03-23 赛诺菲-安万特 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
WO2010068775A2 (en) * 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (de) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
RU2563639C2 (ru) 2009-09-25 2015-09-20 Астеллас Фарма Инк. Замещенные соединения амида
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011159635A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
WO2011159632A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
JP5944823B2 (ja) * 2010-07-02 2016-07-05 あすか製薬株式会社 複素環化合物及びp27Kip1分解阻害剤
SG191041A1 (en) * 2010-12-07 2013-08-30 Amira Pharmaceuticals Inc Polycyclic lpa1 antagonist and uses thereof
WO2012100436A1 (en) * 2011-01-30 2012-08-02 Curegenix Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
CN103596947A (zh) * 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
MX2013013752A (es) * 2011-05-25 2014-08-01 Intermune Inc Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados.
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
EP2783016A1 (de) 2011-11-22 2014-10-01 Intermune, Inc. Verfahren zur diagnose und behandlung von idiopathischer lungenfibrose
JP2015521183A (ja) * 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
ES2667798T3 (es) 2012-12-28 2018-05-14 Ube Industries, Ltd. Compuesto heterocíclico sustituido con halógeno
US10000459B2 (en) * 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
EA038294B1 (ru) * 2013-05-24 2021-08-05 Эпиджен Байосайенсиз, Инк. Гетероциклические соединения, применимые в лечении заболеваний
CN104788343A (zh) * 2014-01-16 2015-07-22 同济大学 一种邻位取代烯丙基氨基甲酸酯类化合物及其制备方法
AU2015281021B9 (en) * 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
HK1252425A1 (zh) 2015-06-05 2019-05-24 Vertex Pharmaceuticals Incorporated 用於治疗脱髓鞘疾病的三唑类药物
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
JP7526096B2 (ja) 2017-12-19 2024-07-31 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
CN112074515B (zh) 2017-12-19 2025-01-10 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
EP3728210B1 (de) 2017-12-19 2026-02-11 Bristol-Myers Squibb Company Isoxazol-n-verknüpfte carbamoylcyclohexylsäuren als lpa-antagonisten
KR102697358B1 (ko) * 2017-12-19 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
CA3104465A1 (en) * 2018-06-18 2019-12-26 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
WO2022013378A1 (en) * 2020-07-16 2022-01-20 Chiesi Farmaceutici S.P.A. Amido cyclohexane acid derivatives as lpa receptor inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1090795A (en) 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5861359A (en) * 1995-07-25 1999-01-19 Fmc Corporation Herbicidal phenylmethoxphenyl heterocycles
WO1998027213A1 (en) * 1996-12-18 1998-06-25 Medical Research Council Lysophosphatidic acid acyltransferase gene and its use
SE9904044D0 (sv) * 1999-11-09 1999-11-09 Astra Ab Compounds
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use

Also Published As

Publication number Publication date
US6964975B2 (en) 2005-11-15
EP1258484B1 (de) 2009-01-14
TWI288136B (en) 2007-10-11
DK1258484T3 (da) 2009-04-20
EP1258484A1 (de) 2002-11-20
EP1258484A4 (de) 2003-04-23
US20030114505A1 (en) 2003-06-19
WO2001060819A1 (en) 2001-08-23
CY1110263T1 (el) 2015-01-14
DE60137405D1 (de) 2009-03-05
PT1258484E (pt) 2009-04-03
ES2320320T3 (es) 2009-05-21
AU2001232340A1 (en) 2001-08-27

Similar Documents

Publication Publication Date Title
ATE420878T1 (de) Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
ATE226581T1 (de) Isoxazole derivate und ihre verwendung als herbizide
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
ECSP045359A (es) Isoxazolinas 5 metiloximetil sustituidas por 3-heteroarilo utilizadas con herbicidas
DE60026509D1 (de) Chinolinderivate als mek enzym-inhibitoren
BRPI0213243B8 (pt) composto heterocíclico aromático contendo um anel oxazol, tiazol ou imidazol, ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
SG165361A1 (en) Antituberculous composition comprising oxazole compounds
BR9508676A (pt) Carbamolicarboxamida composição processos para preparar compostos e a composição e para controlar fungos nocivos e uso compost e das composições
PT832079E (pt) Derivados de hidroxilamina anti-isquemicos e composicoes farmaceuticas
ATE122040T1 (de) Pestizide heterozyklische verbindungen.
BR8003950A (pt) Composicoes herbicidas, baseadas em derivados de m-anilido-uretana
ATE234315T1 (de) Medikamente gegen trhombocytopenie
ES8802413A1 (es) Procedimiento para preparar una composicion herbicida a base de carbamoiloxi-fenilcarbamato y aceite mineral de petroleo
TW200626007A (en) Material for electroluminescent element and electroluminescent element
SE8101703L (sv) Nya isoxazolderivat jemte sett for deras framstellning
DE69217148D1 (de) Isoxazole derivate als lichtschutzmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1258484

Country of ref document: EP